The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure
Open accessAbstract
Key Words: Asia, dapagliflozin, ethnicity; heart failure; heart failure with mildly reduced ejection fraction; heart failure with preserved ejection fraction, regional differences; sodium-glucose cotransporter-2 inhibitor
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This paradigm shift was further solidified by dedicated heart failure trials such as DAPA-HF and EMPEROR-Reduced, which showed meaningful reductions in cardiovascular death and heart failure hospitalizations even among patients without diabetes, establishing a clear class effect [9].”
From Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early cardiovascular outcome trials consistently demonstrated significant reductions in heart failure hospitalizations and improved renal outcomes, with benefits observed irrespective of baseline atherosclerotic cardiovascular disease status.”
From Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of this robust and reproducible evidence base, contemporary cardiology and endocrine guidelines now recommend SGLT2is as foundational therapy for patients with type 2 diabetes and high cardiovascular or renal risk, and as core therapy for heart failure across the ejection-fraction spectrum, independent of glycemic status [9,10].”
From Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Global burden of heart failure: a comprehensive and updated review of epidemiology
Savarese, G., Becher, P. M., Lund, L. H., Seferovic, P. M., Rosano, G. M. C., & Coats, A. J. S. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac013 · Cited by 3,482
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Dokainish, H., Teo, K. K., Zhu, J., Roy, A., AlHabib, K. F., ElSayed, A., Palileo-Villaneuva, L., López-Jaramillo, P. A., Karaye, K. M., Yusoff, K., et al. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30196-1 · Cited by 411
Hao, G., Wang, X., Chen, Z., Zhang, L., Zhang, Y., Wei, B.-Q., Zheng, C., Kang, Y., Jiang, L., Zhu, Z., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1629 · Cited by 399
Heart failure across Asia: Same healthcare burden but differences in organization of care
Reyes, E. B., Ha, J., Firdaus, I., Ghazi, A. M., Phrommintikul, A., Sim, D., Vu, Q. N., Siu, C., Yin, W., & Cowie, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.256 · Cited by 175
The Upcoming Epidemic of Heart Failure in South Asia
Martínez-Amezcua, P., Haque, W. Z., Khera, R., Kanaya, A. M., Sattar, N. A., Lam, C. S. P., Harikrishnan, S., Shah, S. J., Kandula, N. R., Jose, P. O., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007218 · Cited by 89
Lam, C. S. P., Ferreira, J. P., Pfarr, E., Sim, D., Tsutsui, H., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Sattar, N. A., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab360 · Cited by 57
Yazaki, Y., Aizawa, K., Israr, M. Z., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12777 · Cited by 48
Yazaki, Y., Salzano, A., Nelson, C. P., Voors, A. A., Anker, S. D., Cleland, J. G. F., Lang, C. C., Metra, M., Samani, N. J., Ng, L. L., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1550 · Cited by 33
Self-citation
Cited by
Sorted by citations
Obi, M. F., Ahmad, S., & Ezechukwu, K. (2026) · Cureus · doi:10.7759/cureus.106266 · Cited by 1
Metadata
- Authors
- Crisci, G., & Salzano, A.
- Affiliations
- Federico II University Hospital (IT)
- Ospedale Antonio Cardarelli (IT)
- Corresponding author
- Salzano, Andrea
- Venue
- JACC Asia
- Publisher
- Elsevier BV
- Published
- 2024-02
- Volume
- 4
- Issue
- 2
- Pages
- 119-122
- ISSN
- 2772-3747 (ISSN-L)
- PMC
- PMC10866728
- OpenAlex
- W4391559254
- Cited by
- 1
- References
- 17
- Citations by year
- 2026: 1
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- JACC Asia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
